AkzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SDS code : 40980345B

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses

Paint. Professional use Industrial use

Uses advised against

All other uses

Product use : Solvent borne coating for interior use.

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex

France

e-mail address of person responsible for this SDS

: PSRA PAMIERS@akzonobel.com

1.4 Emergency telephone number

National advisory body/Poison Center

Telephone number : (0551) 19240

Supplier

Telephone number : +33 (0)5 34 01 34 01

+33 (0)5 61 60 23 30

Hours of operation :

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation 1/21 AkzoNobel

SECTION 2: Hazards identification

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms







Signal word : Warning

Hazard statements : Flammable liquid and vapor.

Causes skin irritation.
Causes serious eye irritation.
May cause drowsiness or dizziness.

May cause damage to organs through prolonged or repeated exposure.

Harmful to aquatic life with long lasting effects.

Precautionary statements

Prevention: Wear protective gloves. Wear eye or face protection. Keep away from heat, hot

surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapor. Wash hands thoroughly after

handling.

Response : Get medical advice or attention if you feel unwell. IF INHALED: Call a POISON

CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or

attention.

Storage: Store in a well-ventilated place. Keep container tightly closed. Keep cool.

Disposal : Dispose of contents and container in accordance with all local, regional, national

and international regulations.

Hazardous ingredients : n-butyl acetate

Reaction mass of ethylbenzene and xylene

Supplemental label

elements

: Contains methyl methacrylate. May produce an allergic reaction.

Annex XVII - Restrictions on the manufacture,

placing on the market and use of certain dangerous substances, mixtures and

articles

: Not applicable.

Special packaging requirements

Containers to be fitted with child-resistant

: Not applicable.

fastenings

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification

: None known.

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation 2/21 AkzoNobel

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

| Product/ingredient name | Identifiers | % | Regulation (EC) No. 1272/2008 [CLP] | Туре |
|---|---|-----------|---|---------|
| n-butyl acetate | REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1 | ≥25 - ≤50 | Flam. Liq. 3, H226 STOT SE 3, H336 EUH066 | [1] [2] |
| Reaction mass of ethylbenzene and xylene | REACH #: 01-2119488216-32 EC: 905-588-0 | ≥10 - ≤15 | Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | [1] [2] |
| 2-methoxy-1-methylethyl acetate | REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 | ≥10 - ≤25 | Flam. Liq. 3, H226 STOT SE 3, H336 | [1] [2] |
| aromatic hydrocarbons, C9 | REACH #: 01-2119455851-35 EC: 918-668-5 CAS: 128601-23-0 | ≤1.3 | Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 EUH066 | [1] |
| Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics | REACH #: 01-2119463258-33 EC: 919-857-5 | ≤3 | Flam. Liq. 3, H226 STOT SE 3, H336 Asp. Tox. 1, H304 EUH066 | [1] |
| methyl methacrylate | REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6 | <1 | Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335 | [1] [2] |
| cyclohexanone | REACH #: 01-2119453616-35 EC: 203-631-1 CAS: 108-94-1 Index: 606-010-00-7 | ≤0.1 | Flam. Liq. 3, H226 Acute Tox. 4, H332 | [1] [2] |
| cumene | REACH #: 01-2119473983-24 EC: 202-704-5 CAS: 98-82-8 Index: 601-024-00-X | ≤0.1 | Flam. Liq. 3, H226 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 | [1] [2] |
| | | | See Section 16 for the full text of the H statements declared above. | |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

 Date of issue/Date of revision
 : 1-10-2022
 Version
 : 1

 Date of previous issue
 : No previous validation
 3/21
 AkzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SECTION 3: Composition/information on ingredients

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Skin contact

: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Protection of first-aiders

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

 Date of issue/Date of revision
 : 1-10-2022
 Version
 : 1

 Date of previous issue
 : No previous validation
 4/21
 AkzoNobel

SECTION 4: First aid measures

Over-exposure signs/symptoms

Eye contact : Adverse symptoms may include the following:

pain or irritation

watering redness

Inhalation : Adverse symptoms may include the following:

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

Skin contact: Adverse symptoms may include the following:

irritation redness

Ingestion: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

Specific treatments: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing

media

: Use dry chemical, CO₂, water spray (fog) or foam.

Unsuitable extinguishing

media

: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

Hazardous combustion

products

: Decomposition products may include the following materials:

carbon dioxide carbon monoxide halogenated compounds metal oxide/oxides

5.3 Advice for firefighters

Special protective actions

for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

Special protective equipment for fire-fighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation 5/21 AkzoNobel

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

6.3 Methods and materials for containment and cleaning up

Small spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.

6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapor or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

: 1-10-2022 Version :1 Date of issue/Date of revision

AkzoNobel Date of previous issue : No previous validation 6/21

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SECTION 7: Handling and storage

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

| | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne | 50000 tonne |

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

| Product/ingredient name | Exposure limit values |
|--|--|
| n-butyl acetate | DFG MAC-values list (Germany, 7/2019). PEAK: 960 mg/m³, 4 times per shift, 15 minutes. PEAK: 200 ppm, 4 times per shift, 15 minutes. TWA: 480 mg/m³ 8 hours. TWA: 100 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). TWA: 300 mg/m³ 8 hours. TWA: 62 ppm 8 hours. PEAK: 600 mg/m³ 15 minutes. PEAK: 124 ppm 15 minutes. |
| Reaction mass of ethylbenzene and xylene | DFG MAC-values list (Germany, 7/2019). Absorbed through skin. PEAK: 440 mg/m³, 4 times per shift, 15 minutes. PEAK: 100 ppm, 4 times per shift, 15 minutes. TWA: 220 mg/m³ 8 hours. TWA: 50 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). Absorbed through skin. PEAK: 880 mg/m³ 15 minutes. PEAK: 200 ppm 15 minutes. TWA: 440 mg/m³ 8 hours. TWA: 100 ppm 8 hours. |
| 2-methoxy-1-methylethyl acetate | TRGS 900 OEL (Germany, 6/2018). TWA: 270 mg/m³ 8 hours. PEAK: 270 mg/m³ 15 minutes. TWA: 50 ppm 8 hours. PEAK: 50 ppm 15 minutes. DFG MAC-values list (Germany, 7/2018). TWA: 50 ppm 8 hours. PEAK: 50 ppm, 4 times per shift, 15 minutes. TWA: 270 mg/m³ 8 hours. |

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation 7/21 AkzoNobel

PEAK: 270 mg/m³, 4 times per shift, 15 minutes.

methyl methacrylate

DFG MAC-values list (Germany, 7/2019). Skin sensitizer.

PEAK: 420 mg/m³, 4 times per shift, 15 minutes. PEAK: 100 ppm, 4 times per shift, 15 minutes.

TWA: 210 mg/m³ 8 hours. TWA: 50 ppm 8 hours.

TRGS 900 OEL (Germany, 3/2020).

PEAK: 420 mg/m³ 15 minutes. PEAK: 100 ppm 15 minutes. TWA: 210 mg/m³ 8 hours. TWA: 50 ppm 8 hours.

cyclohexanone

cumene

TRGS 900 OEL (Germany, 3/2020). Absorbed through skin.

PEAK: 80 mg/m³ 15 minutes. PEAK: 20 ppm 15 minutes. TWA: 80 mg/m³ 8 hours. TWA: 20 ppm 8 hours.

DFG MAC-values list (Germany, 7/2019). Absorbed through

skin.

DFG MAC-values list (Germany, 7/2019). Absorbed through

skin.

PEAK: 200 mg/m³, 4 times per shift, 15 minutes. PEAK: 40 ppm, 4 times per shift, 15 minutes.

TWA: 50 mg/m³ 8 hours. TWA: 10 ppm 8 hours.

TRGS 900 OEL (Germany, 3/2020). Absorbed through skin.

PEAK: 200 mg/m³ 15 minutes. PEAK: 40 ppm 15 minutes. TWA: 50 mg/m³ 8 hours. TWA: 10 ppm 8 hours.

Recommended monitoring procedures

: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

8/21

DNELs/DMELs

| Product/ingredient name | Туре | Exposure | Value | Population | Effects |
|-------------------------|------|-------------------------|------------------------------|--------------------|----------|
| n-butyl acetate | DNEL | Long term Oral | 3.4 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Dermal | 3.4 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Dermal | 7 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 12 mg/m³ | General population | Systemic |
| | DNEL | Long term Inhalation | 48 mg/m³ | Workers | Systemic |
| | DNEL | Long term Inhalation | 102.34 mg/ m ³ | General population | Local |
| | DNEL | Long term | 480 mg/m ³ | Workers | Local |

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation

| Inhalation Short term Demual Short term Demu | 3I | ECTION 6. Exposure cont | 1015/h | ersonal prote | Cuon | | |
|--|----|-----------------------------------|--------|--------------------|------------------------|-------------------------|--------------|
| ONEL ONEL Ong term Doublation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | Inhalation | | | |
| Inhalation DNEL Short term Short ter | | | DNFI | | 859 7 ma/ | General | Local |
| DNEL Chort term inhalation DNEL Cong term Oral bright or inhalation DNEL Cong term Oral DNEL Cong term Oral bright or inhalation DNEL Cong term Oral DNED DNED DNED DNED DNED DNED DNED DNE | | | DIVLL | | | | Local |
| DNEL | | | DNEI | | | | Cyatamia |
| Reaction mass of ethylbenzene and xylene Reaction mass of ethylbenzene and xylene DNEL Dong term chalation DNEL Cong term Dermal DNEL Cong term chalation DNEL Cong term | | | DINEL | | | | Systemic |
| Reaction mass of ethylbenzene and xylene DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Cong term Inhalation DNEL Co | | | 5 | | | | |
| Reaction mass of ethylbenzene and xylene DNEL long term oral long term linalation on DNEL long term oral long | | | DNEL | | 960 mg/m³ | Workers | Local |
| Reaction mass of ethylbenzene and xylene DNEL Long term Oral Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DRED DNEL Long term DNEL DNET DNET DNET DNET DNET DNET DNET DNET | | | | | | | |
| Reaction mass of ethylbenzene and xylene DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Long term Dermal DNEL Long term DNEL DNEL DNET DNEL DNET DNET DNET DNET DNET DNET DNET DNET | | | DNEL | Short term | 960 mg/m ³ | Workers | Systemic |
| DNEL Long term Inhalation DNEL Long term Domal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Domal DNEL Long term Domal DNEL Long term Domal Inhalation DNEL Long term Domal Inhalation DNEL Long term Domal DNEL Long term Inhalation DNEL Long term Domal DNEL DNET DNET DNET DNET DNET DNET DNET DNET | | | | Inhalation | _ | | |
| DNEL Long term Inhalation DNEL Long term Domal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Domal DNEL Long term Domal DNEL Long term Domal Inhalation DNEL Long term Domal Inhalation DNEL Long term Domal DNEL Long term Inhalation DNEL Long term Domal DNEL DNET DNET DNET DNET DNET DNET DNET DNET | | Reaction mass of ethylbenzene and | DNEL | Long term Oral | 1.6 ma/ka | General | Systemic |
| DNEL Long term permal phalation DNEL long term phalation DNEL lon | | | | 3 | | | , |
| Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term DNEL DNEL Short term DNEL DNEL Short term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | Aylone | DNEI | Long term | | | Systemic |
| DNEL Long term Dermal DNEL Cong term Dermal DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term DNEL Short term DNEL Short term Short ter | | | DIVLL | | 14.0 1119/111 | | Cystoniio |
| Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Long term DNEL Short term DNEL Long term DNEL Long term DNEL Long term DNEL Short term DNEL Shor | | | DNEI | | 77 ma/m³ | | Cyatamia |
| DNEL Long term Dermal DNEL Cage my methyl methacrylate DNEL DNEL Long term Dermal DNEL Cage my methyl methacrylate DNEL DNEL Long term Dermal DNEL Cong term Dermal Inhalation DNEL Cong term Dermal DNEL Cong term DNEL Cong term Dermal DNED Derma D | | | DINEL | | 77 mg/m | WOIKEIS | Systemic |
| DNEL Long term Dermal bw/day bw/day hopopulation bw/day la80 mg/kg bw/day 289 mg/m² lnhalation DNEL Short term lnhalation DNEL Long term Dermal lnhalation DNEL Long term Dermal lnhalation DNEL Long term lnhalation DNEL Long term Dermal DNEL Long term DNEL Long term DNEL Short term DNEL Short term DNEL Long term DNEL Short term DNEL Short term DNEL Short term DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL Short term | | | 5 | | 400 " | | |
| DNEL Long term Dermal 180 mg/kg bw/day 289 mg/m² long term Local bw/day 289 mg/m² long term Lo | | | DNEL | Long term Dermal | | | Systemic |
| DNEL Short term Inhalation Inhala | | | | | | | |
| DNEL Short term Inhalation DNEL Cong term Dermal Systemic DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNEL | Long term Dermal | 180 mg/kg | Workers | Systemic |
| Inhalation Short term Unhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Dneg term DNED DNED DNED DNED DNED DNED DNED DNE | | | | | bw/day | | |
| Inhalation Short term Unhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Dneg term DNED DNED DNED DNED DNED DNED DNED DNE | | | DNEL | Short term | 289 mg/m ³ | Workers | Local |
| methyl methacrylate DNEL Short term Long term Dermal Suz mg/kg bw/day DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal Imple Short term Dermal DNEL Long term Dermal Inhalation DNEL Short term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL DNEL Cong term Dermal Inhalation DNEL DNEL | | | | | J. | | |
| methyl methacrylate DNEL Long term Dermal B.2 mg/kg bw/day 13.67 mg/kg bw/day 14.7 mg/m² by/day bw/day | | | DNFI | | 289 ma/m³ | Workers | Systemic |
| methyl methacrylate DNEL Long term Dermal Long term Dermal Systemic | | | J. 1LL | | _00 mg/m | ., 011010 | - you - 1110 |
| DNEL Long term Dermal Dwelday 13.67 mg/ kg bw/day 13.67 mg/ kg bw/day 74.3 mg/m³ General population General population General population General population Workers Systemic population General population Workers Local population Workers Local population Workers Local population Workers Systemic population Workers Local population Workers Systemic population Workers Systemic population Short term Dermal Demail DNEL Long term Dermal Dnel DNEL Long term Oral Short term Damal Dnel Long term Dermal Dnel Dnel Long term Dermal Dnel Dnel Long term Dermal Dnel Dnel Dnel Dnel Dnel Dnel Dnel Dne | | methyl methacrylate | DNEI | | 8.2 ma/ka | Ceneral | Systemic |
| DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL DNEL Short term DNEL DNEL Short term DNEL DNEL Short term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | metryi metraciyiate | DINEL | Long term Dermai | | | Systemic |
| DNEL Long term Inhalation DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Oral DNEL Short term Dermal DNEL Long term DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL Short term Dermal DNEL Dnet DNEL Short term DNEL Dnet DNED DNEL Dnet DNEL Dnet DNED DNEL Dnet DNED DNEL Dnet DNED DNED DNED DNED DNED DNED DNED DNE | | | | | , | | |
| DNEL Long term Inhalation DNEL DNEL Long term Dermal Inhalation DNEL DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL Dneg term Dermal Dneg term Dermal DNEL Dneg term Dermal DNEL Dneg term Dermal Dneg term Dneg term Dermal Dneg term Dneg | | | DNEL | Long term Dermal | | Workers | Systemic |
| Inhalation Long term Lon | | | | | | | |
| DNEL long term Inhalation DNEL long term Dermal DNEL long term Oral DNEL long term Oral DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term DNEL Short term DNEL Short term DNEL Short term DNEL DNEL Long term DNEL Short term DNEL DNEL Long term DNEL Short term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNEL | Long term | 74.3 mg/m ³ | General | Systemic |
| DNEL long term Inhalation DNEL long term Dermal DNEL long term Oral DNEL long term Oral DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term Dermal DNEL long term DNEL Short term DNEL Short term DNEL Short term DNEL DNEL Long term DNEL Short term DNEL DNEL Long term DNEL Short term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | Inhalation | | population | |
| Inhalation Long term Inhalation DNEL Short term Dermal DNEL Long term Dormal Long term Dormal DNEL Long term Dormal DNEL DORMAN DOR | | | DNEL | Long term | 104 mg/m ³ | General | Local |
| DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Oral DNEL Long term Dermal DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Cocal DNEL Cocal DNEL Short term Dermal DNEL Cocal DNEL Cocal DNEL Short term Dermal DNEL Cocal | | | | | J | | |
| Inhalation Long term Inhalation DNEL Short term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Long term Oral DNEL Short term Dermal DNEL Short term Domplation DNEL Domp term Domplation Domplation Domplation Domplation Domplat | | | DNFI | | 208 ma/m³ | | Local |
| cyclohexanone DNEL Long term Inhalation Short term Dermal One Short term Dermal Derma | | | DIVLL | | 200 mg/m | Workers | Local |
| cyclohexanone DNEL Short term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Oral Short term Oral Short term Oral Short term Dermal DNEL Short term Dermal Systemic DNEL Short term Dermal Systemic DNEL Short term Dermal Systemic DNEL Short term Dermal Short term Dermal Systemic DNEL Short term Short term Systemic DNEL Systemic DNEL Short term Short te | | | DNEI | | 208 ma/m³ | Morkers | Systemic |
| cyclohexanone DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNE | | | DINEL | | 200 mg/m | VVOIKEIS | Systemic |
| DNEL Long term Dermal bw/day 1 mg/kg bw/day population General bw/day population General population Systemic bw/day population 4 mg/kg bw/day Workers Systemic bw/day Workers Systemic bw/day Workers Systemic bw/day DNEL Long term Dermal Inhalation DNEL Long term 10 mg/m³ General population DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation Short term Short | | | DAIEI | | 4 // | 0 | 0 |
| DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long term DNEL Long term Inhalation DNEL Short term DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation Short term Inhala | | cyclonexanone | DNEL | Snort term Dermai | | | Systemic |
| DNEL Short term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dnem DNEL Dnem Dnem Dnem DNEL Dnem Dnem Dnem Dnem Dnem Dnem Dnem Dnem | | | | | • | | |
| DNEL Short term Oral 1.5 mg/kg bw/day DNEL Long term Oral 1.5 mg/kg bw/day DNEL Short term Dermal 5 bw/day DNEL Long term Dermal 6 bw/day DNEL Long term Dermal 7 bw/day DNEL Long term Dermal 8 bw/day DNEL Long term 10 mg/m³ General population DNEL Long term 10 mg/m³ General population DNEL Long term 10 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers DNEL Short term 10 mg/m³ Workers | | | DNEL | Long term Dermal | | | Systemic |
| DNEL Long term Oral 1.5 mg/kg bw/day bw/day bw/day bw/day DNEL Long term Dermal DNEL Long term Dermal Long term 10 mg/m³ DNEL Short term 10 mg/m³ DNEL Long term 10 mg/m³ Workers Local 10 DNEL Long term 10 mg/m³ Workers Systemic 10 mg/m³ Workers Local 10 mg/m³ Workers 10 | | | | | bw/day | population | |
| DNEL Short term Dermal DNEL Long term Inhalation DNEL Short term Dnetmal DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation Inh | | | DNEL | Short term Oral | 1.5 mg/kg | General | Systemic |
| DNEL Short term Dermal DNEL Long term Inhalation DNEL Short term Dnetmal DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation Inh | | | | | bw/day | population | |
| DNEL Short term Dermal bw/day bw/day bw/day bw/day Workers Systemic DNEL Long term Dermal 4 mg/kg bw/day Workers Systemic DNEL Long term 10 mg/m³ General population population General population DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers Local population DNEL Long term 40 mg/m³ Workers Systemic population DNEL Long term 40 mg/m³ Workers Local population DNEL Short term 80 mg/m³ Workers Local | | | DNEL | Long term Oral | | | Systemic |
| DNEL Short term Dermal 4 mg/kg bw/day DNEL Long term Dermal 4 mg/kg bw/day DNEL Long term 10 mg/m³ General population DNEL Long term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term 80 mg/m³ Workers Local | | | | | | | • |
| DNEL Long term Dermal bw/day DNEL Long term 10 mg/m³ General population DNEL Long term 20 mg/m³ General population DNEL Short term 10 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ General population DNEL Short term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers DNEL Short term 10 mg/m³ Workers | | | DNFI | Short term Dermal | | | Systemic |
| DNEL Long term Dermal bw/day DNEL Long term 10 mg/m³ General population DNEL Long term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ General population DNEL Long term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers Local | | | | | | · · · · · · · · · · · · | , |
| DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | DNE | Long term Dermal | , | Workers | Systemic |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | DINCL | Long will Delillal | | VVOINGIO | Cystollilo |
| Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | DNE | Long torm | | Coporal | Systemis |
| DNEL Long term Inhalation DNEL Short term 20 mg/m³ General population DNEL Short term 20 mg/m³ General population DNEL Short term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers Local | | | DINEL | | io ing/m° | | Systemic |
| Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | D | | 00 / 0 | | |
| DNEL Short term lnhalation 20 mg/m³ General population Short term lnhalation 40 mg/m³ General population Local population DNEL Long term lnhalation DNEL Long term lnhalation DNEL Long term lnhalation DNEL Short term lnhalation DNEL Short term lnhalation Somg/m³ Workers Local Short term lnhalation Somg/m³ Workers Local Short term lnhalation Somg/m³ Seneral population Local Systemic | | | DNEL | | 20 mg/m ³ | | Local |
| Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | | | | | |
| DNEL Short term Inhalation DNEL Long term 40 mg/m³ General population DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Long term 40 mg/m³ Workers DNEL Short term 80 mg/m³ Workers Local | | | DNEL | | 20 mg/m ³ | | Systemic |
| DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | | Inhalation | | population | |
| Inhalation DNEL Long term 40 mg/m³ Workers Local Inhalation DNEL Long term 40 mg/m³ Workers Systemic Inhalation DNEL Short term 80 mg/m³ Workers Local Inhalation | | | DNEL | Short term | 40 mg/m³ | | Local |
| DNEL Long term 40 mg/m³ Workers Local DNEL Long term 40 mg/m³ Workers Systemic DNEL Long term 40 mg/m³ Workers Systemic Inhalation 80 mg/m³ Workers Local | | | | | | | |
| DNEL Long term Long term 40 mg/m³ Workers Systemic Inhalation DNEL Short term 80 mg/m³ Workers Local Inhalation | | | DNEL | | 40 ma/m³ | | Local |
| DNEL Long term 40 mg/m³ Workers Systemic Inhalation DNEL Short term 80 mg/m³ Workers Local Inhalation | | | | | | | |
| DNEL Short term 80 mg/m³ Workers Local Inhalation | | | DNEI | | 10 mg/m ³ | Workers | Systemic |
| DNEL Short term 80 mg/m³ Workers Local Inhalation | | | DINEL | | TO MIG/III | VVOINGIS | Cysternic |
| Inhalation | | | ראבי | | 00 m a/m 3 | Morkora | Local |
| | | | DINEL | | ou mg/m² | vvoikeis | Local |
| DNEL Short term 80 mg/m³ Workers Systemic | | | D | | 00 / 3 | VA / I | 0 |
| | | | DINEL | Snort term | ชบ mg/m³ | vvorkers | Systemic |

Date of issue/Date of revision
Date of previous issue

: 1-10-2022

: No previous validation

Version .

9/21

| • | | • | | | |
|--------|------|--------------------------|-----------------------|--------------------|----------|
| | | Inhalation | | | |
| cumene | DNEL | Long term Dermal | 1.2 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Oral | 5 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Dermal | 15.4 mg/ kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 16.6 mg/m³ | General population | Systemic |
| | DNEL | Long term Inhalation | 100 mg/m ³ | | Systemic |
| | DNEL | Short term Inhalation | 250 mg/m ³ | Workers | Local |

PNECs

No PNECs available.

8.2 Exposure controls

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time >480 minutes according to EN374) is recommended. Recommended gloves: Viton 8 or Nitrile, thickness 2 0.38 mm. When only brief contact is expected, a glove with protection class of 2 or higher (breakthrough time >30 minutes according to EN374) is recommended. Recommended gloves: Nitrile, thickness 2 0.12 mm.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

The performance or effectiveness of the glove may be reduced by physical/chemical damage and poor maintenance.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

Date of issue/Date of revision
Date of previous issue

: 1-10-2022 : No previous validation **Version** : 1 10/21

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid. Color : White.

Odor : Characteristic. : Not available. **Odor threshold** : Not available. Melting point/freezing point : Not available. Initial boiling point and : Not available.

boiling range

: Closed cup: 28°C Flash point **Evaporation rate** : Not available. : Not available. Flammability (solid, gas) Upper/lower flammability or : Not available.

explosive limits

Vapor pressure : Not available.

Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Vapor density

Weighted average: 4.05 (Air = 1)

: 1.018 g/cm³ Density

Solubility(ies) : Insoluble in the following materials: cold water.

Partition coefficient: n-octanol/: Not available.

water

Auto-ignition temperature : Not available. **Decomposition temperature** : Not available.

Viscosity : Kinematic (room temperature): 10.81 cm²/s

Kinematic (40°C): 1.01 cm²/s

: 1-10-2022 Date of issue/Date of revision Version : 1

AkzoNobel Date of previous issue : No previous validation 11/21

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SECTION 10: Stability and reactivity

: No specific test data related to reactivity available for this product or its ingredients. 10.1 Reactivity

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld,

braze, solder, drill, grind or expose containers to heat or sources of ignition.

10.5 Incompatible materials : Reactive or incompatible with the following materials:

oxidizing materials

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products

should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|--|-----------------------|------------|-------------------------|----------|
| n-butyl acetate | LC50 Inhalation Gas. | Rat | 390 ppm | 4 hours |
| | LC50 Inhalation Vapor | Mouse | 6 g/m³ | 2 hours |
| | LD50 Dermal | Rabbit | >17600 mg/kg | - |
| | LD50 Intraperitoneal | Mouse | 1230 mg/kg | - |
| | LD50 Oral | Guinea pig | 4700 mg/kg | - |
| | LD50 Oral | Mouse | 6 g/kg | - |
| | LD50 Oral | Rabbit | 3200 mg/kg | - |
| | LD50 Oral | Rat | 10768 mg/kg | - |
| Reaction mass of ethylbenzene and xylene | LC50 Inhalation Gas. | Rat | 5000 ppm | 4 hours |
| methyl methacrylate | LC50 Inhalation Vapor | Mouse | 18500 mg/m ³ | 2 hours |
| | LC50 Inhalation Vapor | Rat | 78000 mg/m ³ | 4 hours |
| | LD50 Dermal | Rabbit | >5 g/kg | - |
| | LD50 Intraperitoneal | Guinea pig | 1890 mg/kg | _ |
| | LD50 Intraperitoneal | Mouse | 945 mg/kg | - |
| | LD50 Intraperitoneal | Rat | 1328 mg/kg | - |
| | LD50 Oral | Guinea pig | 5954 mg/kg | - |
| | LD50 Oral | Mouse | 3625 mg/kg | - |
| | LD50 Oral | Rabbit | 8700 mg/kg | - |
| | LD50 Oral | Rat | 7872 mg/kg | - |
| | LD50 Subcutaneous | Guinea pig | 5954 mg/kg | - |
| | LD50 Subcutaneous | Mouse | 5954 mg/kg | - |
| | LD50 Subcutaneous | Rat | 7088 mg/kg | - |
| cyclohexanone | LC50 Inhalation Gas. | Rat | 8000 ppm | 4 hours |
| | LD50 Dermal | Rabbit | 1 mL/kg | - |
| | LD50 Intraperitoneal | Guinea pig | 930 mg/kg | - |
| | LD50 Intraperitoneal | Mouse | 1230 mg/kg | - |
| | LD50 Intraperitoneal | Mouse | 1230 mg/kg | - |
| | LD50 Intraperitoneal | Rabbit | 1540 mg/kg | - |
| | LD50 Intraperitoneal | Rabbit | 1540 mg/kg | - |
| | LD50 Intraperitoneal | Rat | 1130 mg/kg | - |
| | LD50 Intraperitoneal | Rat | 1130 mg/kg | - |
| | LD50 Oral | Mouse | 1400 mg/kg | - |
| | LD50 Oral | Rat | 1800 mg/kg | - |
| | LD50 Oral | Rat | 1620 uL/kg | - |
| | LD50 Subcutaneous | Rat | 2170 mg/kg | - |
| 1 | | | | <u> </u> |

Date of issue/Date of revision : 1-10-2022 Version : 1 Date of previous issue 12/21

: No previous validation

SECTION 11: Toxicological information

| | _ | | | |
|--------|-----------------------|--------|-------------------------|---------|
| cumene | LC50 Inhalation Vapor | Mouse | 15300 mg/m³ | 2 hours |
| | LC50 Inhalation Vapor | Mouse | 10 g/m³ | 7 hours |
| | LC50 Inhalation Vapor | Mouse | 10000 mg/m ³ | 7 hours |
| | LC50 Inhalation Vapor | Rat | 39000 mg/m ³ | 4 hours |
| | LD50 Dermal | Rabbit | 12300 uL/kg | - |
| | LD50 Oral | Mouse | 12750 mg/kg | - |
| | LD50 Oral | Rat | 2.9 g/kg | - |
| | LD50 Oral | Rat | 1400 mg/kg | - |
| | | | | |

Conclusion/Summary

: Not available.

Irritation/Corrosion

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|--|--------------------------|---------|-------|---------------|-------------|
| n-butyl acetate | Eyes - Moderate irritant | Rabbit | - | 100 mg | - |
| | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| Reaction mass of ethylbenzene and xylene | Eyes - Mild irritant | Rabbit | - | 87 mg | - |
| | Eyes - Severe irritant | Rabbit | - | 24 hours 5 | - |
| | | | | mg | |
| | Skin - Mild irritant | Rat | - | 8 hours 60 UI | - |
| | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| | Skin - Moderate irritant | Rabbit | - | 100 % | - |
| cyclohexanone | Eyes - Severe irritant | Rabbit | - | 24 hours 250 | - |
| | | | | ug | |
| | Eyes - Severe irritant | Rabbit | - | 20 mg | - |
| | Skin - Mild irritant | Rabbit | - | 500 mg | - |
| cumene | Eyes - Mild irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| | Eyes - Mild irritant | Rabbit | - | 86 mg | - |
| | Skin - Mild irritant | Rabbit | - | 24 hours 10 | - |
| | [| | | mg | |
| | Skin - Moderate irritant | Rabbit | - | 24 hours 100 | - |
| | | | | mg | |

Conclusion/Summary

: Not available.

Sensitization

Conclusion/Summary: Not available.

Mutagenicity

Conclusion/Summary: Not available.

Carcinogenicity

Conclusion/Summary: Not available.

Reproductive toxicity

Conclusion/Summary: Not available.

Teratogenicity

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|---|------------|-------------------|------------------------------|
| n-butyl acetate | Category 3 | - | Narcotic effects |
| Reaction mass of ethylbenzene and xylene | Category 3 | - | Respiratory tract irritation |
| 2-methoxy-1-methylethyl acetate | Category 3 | - | Narcotic effects |
| aromatic hydrocarbons, C9 | Category 3 | - | Respiratory tract irritation |
| | Category 3 | | Narcotic effects |
| Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, | Category 3 | - | Narcotic effects |

Date of issue/Date of revision : 1-10-2022 Version : 1

 Date of previous issue
 : No previous validation
 13/21

 AkzoNobel

SECTION 11: Toxicological information

| <2% aromatics methyl methacrylate | Category 3 | - | Respiratory tract irritation | |
|-----------------------------------|------------|---|------------------------------|--|
|-----------------------------------|------------|---|------------------------------|--|

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|--|------------|-------------------|---------------|
| Reaction mass of ethylbenzene and xylene | Category 2 | - | - |

Aspiration hazard

| Product/ingredient name | Result |
|--|--|
| Reaction mass of ethylbenzene and xylene aromatic hydrocarbons, C9 Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 |

Information on the likely routes of exposure

: Not available.

Potential acute health effects

Eye contact : Causes serious eye irritation.

Inhalation : Can cause central nervous system (CNS) depression. May cause drowsiness or

dizziness.

Skin contact: Causes skin irritation.

Ingestion: Can cause central nervous system (CNS) depression.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact: Adverse symptoms may include the following:

pain or irritation watering redness

Inhalation : Adverse symptoms may include the following:

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

Skin contact: Adverse symptoms may include the following:

irritation redness

Ingestion: No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

Date of issue/Date of revision : 1-10-2022 Version : 1

Date of previous issue : No previous validation 14/21 AkzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 FRS-40 SEMI-GLOSS BASE PREMIUM BEIGE AIC 3.45

SECTION 11: Toxicological information

Conclusion/Summary : Not available.

General : May cause damage to organs through prolonged or repeated exposure.

: No known significant effects or critical hazards. Carcinogenicity Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards.

Other information : Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself.

Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

| Product/ingredient name | Result | Species | Exposure |
|-------------------------|-------------------------------------|--|----------|
| n-butyl acetate | Acute LC50 32 mg/l Marine water | Crustaceans - Artemia salina | 48 hours |
| | Acute LC50 100000 µg/l Fresh water | Fish - Lepomis macrochirus | 96 hours |
| | Acute LC50 18000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 185000 µg/l Marine water | Fish - Menidia beryllina | 96 hours |
| | Acute LC50 62000 µg/l Fresh water | Fish - Danio rerio | 96 hours |
| Reaction mass of | Acute LC50 13400 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| ethylbenzene and xylene | | | |
| methyl methacrylate | Acute LC50 191000 μg/l Fresh water | Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling) | 96 hours |
| | Acute LC50 159100 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 160200 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 150000 µg/l Fresh water | Fish - Pimephales promelas - Adult | 96 hours |
| | Acute LC50 130000 μg/l Fresh water | Fish - Pimephales promelas - Adult | 96 hours |
| cyclohexanone | Acute EC50 32.9 mg/l Fresh water | Algae - Chlamydomonas reinhardtii - Exponential growth phase | 72 hours |
| | Acute LC50 630000 μg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 527000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 732000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| cumene | Acute EC50 2600 μg/l Fresh water | Algae - Pseudokirchneriella subcapitata | 72 hours |
| | Acute EC50 7.4 mg/l Marine water | Crustaceans - Artemia sp Nauplii | 48 hours |
| | Acute EC50 7.5 mg/l Marine water | Crustaceans - Artemia sp Nauplii | 48 hours |
| | Acute EC50 10.6 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 48 hours |
| | Acute EC50 10.6 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 48 hours |
| | Acute EC50 11.2 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 48 hours |
| | Acute LC50 7.4 mg/l Marine water | Crustaceans - Artemia sp Nauplii | 48 hours |
| | Acute LC50 8 mg/l Marine water | Crustaceans - Artemia sp Nauplii | 48 hours |
| | Acute LC50 20.3 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 48 hours |
| | Acute LC50 20.3 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 48 hours |

Date of issue/Date of revision : 1-10-2022 Version : 1 15/21

Date of previous issue : No previous validation

SECTION 12: Ecological information Acute LC50 6320 µg/l Fresh water Fish - Pimephales promelas 96 hours Acute LC50 5100 µg/l Fresh water Fish - Poecilia reticulata 96 hours Acute LC50 2700 µg/l Fresh water Fish - Oncorhynchus mykiss 96 hours

Conclusion/Summary : Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|-------------------------|--------|-------------|-----------|
| n-butyl acetate | 2.3 | - | low |
| Reaction mass of | 3.12 | 8.1 to 25.9 | low |
| ethylbenzene and xylene | | | |
| 2-methoxy-1-methylethyl | 1.2 | - | low |
| acetate | | | |
| methyl methacrylate | 1.38 | - | low |
| cyclohexanone | 0.86 | - | low |
| cumene | 3.55 | 35.48 | low |

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimized wherever possible.

> Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and nonrecyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of

all authorities with jurisdiction.

: The classification of the product may meet the criteria for a hazardous waste. **Hazardous waste**

Disposal considerations : Do not allow to enter drains or watercourses.

Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no

longer apply and the appropriate code should be assigned.

For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

| Waste code | Waste designation |
|---------------|---|
| EWC 08 01 11* | waste paint and varnish containing organic solvents or other hazardous substances |

| Date of issue/Date of revision | : 1-10-2022 | Version :1 | |
|--------------------------------|--------------------------|------------|-----------|
| Date of previous issue | : No previous validation | 16/21 | AkzoNobel |

SECTION 13: Disposal considerations

Packaging

Methods of disposal

: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Disposal considerations

: Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers.

Empty containers must be scrapped or reconditioned.

Dispose of containers contaminated by the product in accordance with local or

national legal provisions.

Special precautions

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

| | ADR/RID | IMDG | IATA |
|------------------------------------|---------|--------|--------|
| 14.1 UN number | UN1263 | UN1263 | UN1263 |
| 14.2 UN proper shipping name | PAINT | PAINT | PAINT |
| 14.3 Transport hazard class(es) | 3 | 3 | 3 |
| 14.4 Packing group | III | III | III |
| 14.5 Environmental hazards | No. | No. | No. |

Additional information

ADR/RID

: Viscous liquid exception This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1.

Tunnel code (D/E)

IMDG

: Emergency schedules F-E, S-E

<u>Viscous liquid exception</u> This class 3 viscous liquid is not subject to regulation in

packagings up to 450 L according to 2.3.2.5.

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not applicable.

: 1-10-2022 Date of issue/Date of revision Version : 1 **AkzoNobel** Date of previous issue : No previous validation 17/21

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorization

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable.

on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Other EU regulations

VOC

: The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the

product label and/or technical data sheet for further information.

VOC for Ready-for-Use

Mixture

: Not applicable.

Industrial emissions (integrated pollution

prevention and control) -

Industrial emissions

: Not listed

: Listed

(integrated pollution prevention and control) -

Water

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Seveso Directive

This product is controlled under the Seveso Directive.

Danger criteria

Category

P₅c

National regulations

Industrial use

: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.

| Product/ingredient name | List name | Name on list | Classification | Notes |
|--|---------------------|---|----------------|-------|
| n-butyl acetate | DFG MAC-values list | n-Butyl acetate | Listed | - |
| Reaction mass of ethylbenzene and xylene | DFG MAC-values list | Xylene (all isomers) | Listed | - |
| 2-methoxy-1-methylethyl acetate | DFG MAC-values list | 1-Methoxypropyl- 2-acetate; Propylene glycol 1-methyl ether- 2-acetate | Listed | - |
| methyl methacrylate | DFG MAC-values list | Methyl methacrylate; Methacrylic acid methyl ester | Listed | - |

Date of issue/Date of revision : 1-10-2022 Version : 1 18/21

Date of previous issue : No previous validation

SECTION 15: Regulatory information

| lovolohovanono | DFG MAC-values list | Cvclohexanone | I/2 | 1 | ĭ |
|----------------|-----------------------|-------------------|------|---|---|
| cyclohexanone | DEG IVIAC-Values list | Cyclonexamone | l vo | - | 1 |
| cumene | DFG MAC-values list | Isopropylbenzene; | K3 | - | l |
| | | Cumene | | | l |

Storage class (TRGS 510) : 3 **Hazardous incident ordinance**

Hazard class for water

Technical instruction on

air quality control

: TA-Luft Number 5.2.5: 66.5%

AOX : The product contains organically bound halogens and can contribute to the AOX

value in waste water.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

: Not determined. Europe

15.2 Chemical Safety

Assessment

: No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and

: ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

acronyms

1272/2008]

DMEL = Derived Minimal Effect Level

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent. Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification | Justification |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226 | On basis of test data |
| Skin Irrit. 2, H315 | Calculation method |
| Eye Irrit. 2, H319 | Calculation method |
| STOT SE 3, H336 | Calculation method |
| STOT RE 2, H373 | Calculation method |
| Aquatic Chronic 3, H412 | Calculation method |

: 1-10-2022 Date of issue/Date of revision Version : 1 **AkzoNobel** Date of previous issue : No previous validation 19/21

SECTION 16: Other information

Full text of abbreviated H statements

| H225 | Highly flammable liquid and vapor. |
|--------|--|
| H226 | Flammable liquid and vapor. |
| H304 | May be fatal if swallowed and enters airways. |
| H312 | Harmful in contact with skin. |
| H315 | Causes skin irritation. |
| H317 | May cause an allergic skin reaction. |
| H319 | Causes serious eye irritation. |
| H332 | Harmful if inhaled. |
| H335 | May cause respiratory irritation. |
| H336 | May cause drowsiness or dizziness. |
| H373 | May cause damage to organs through prolonged or repeated |
| | exposure. |
| H411 | Toxic to aquatic life with long lasting effects. |
| H412 | Harmful to aquatic life with long lasting effects. |
| EUH066 | Repeated exposure may cause skin dryness or cracking. |

Full text of classifications [CLP/GHS]

| ACUTE TOXICITY - Category 4 |
|--|
| AQUATIC HAZARD (LONG-TERM) - Category 2 |
| AQUATIC HAZARD (LONG-TERM) - Category 3 |
| ASPIRATION HAZARD - Category 1 |
| SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2 |
| FLAMMABLE LIQUIDS - Category 2 |
| FLAMMABLE LIQUIDS - Category 3 |
| SKIN CORROSION/IRRITATION - Category 2 |
| SKIN SENSITIZATION - Category 1 |
| SPECIFIC TARGET ORGAN TOXICITY (REPEATED |
| EXPOSURE) - Category 2 |
| SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) - |
| Category 3 |
| |

Date of printing : 1 October 2022

Date of issue/ Date of : 1 October 2022

revision

. 1 October 2022

Date of previous issue : No previous validation

Version : 1 Unique ID :

Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

Date of issue/Date of revision: 1-10-2022Version: 1Date of previous issue: No previous validation20/21AkzoNobel



Date of issue/Date of revision

Date of previous issue

: No previous validation

Version : 1 21/21